Cite
HARVARD Citation
Shum, M. et al. (n.d.). 311PEarly results from an open-label phase 1b/II study of eribulin mesylate (EM) + pegvorhyaluronidase alfa (PEGHP20) combination for the treatment of patients with HER2-negative, high-hyaluronan (HA) metastatic breast cancer (MBC). Annals of oncology. p. . [Online].